# Regeneron (REGN) — Earnings

REGN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/regn/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $14.29 |
| EPS estimate | $10.16 |
| EPS surprise | +40.69% |
| Revenue surprise | +12.40% |
| Revenue | $4.3B |
| Revenue estimate | $3.8B |
| Reported | Jul 30, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/f3232d53-4b90-2ed2-41f9-f3ddf45aa2c8.html) |

Regeneron reported Q2 2026 results on July 30, 2026. Earnings per share came in at $14.29, ahead of the $10.16 estimate by 40.69%. Revenue was $4.3 billion, 12.4% above the $3.8 billion consensus. Compared with Q2 2025, EPS rose about 11% from $12.89 and revenue rose about 16% from $3.7 billion. Both were the highest quarterly figures since Q4 2021.

The longer record shows earnings holding in a narrow band while revenue grew. Annual EPS was $44.96 in 2022, $43.78 in 2023, $45.64 in 2024 and $44.38 in 2025. Annual revenue rose about 18% over that span, from $12.2 billion to $14.4 billion. The first half of 2026 adds up to $23.76 per share, about 13% more than a year earlier, on revenue up about 18%. Q4 2021 holds the highs in the table, at $23.72 per share and $5.0 billion in revenue. The low was Q1 2025, at $8.22. Over the last 20 quarters, Regeneron topped the EPS estimate 18 times. Both misses came in first quarters.

Regeneron reported Q3 results between October 28 and November 4 in each of the past five years. That points to late October or early November 2026 for the next report.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 30, 2026 | $10.16 | $14.29 | 40.69% | $3.8B | $4.3B |
| Q1 2026 | Apr 29, 2026 | $8.91 | $9.47 | 6.24% | $3.5B | $3.6B |
| Q4 2025 | Jan 30, 2026 | $10.74 | $11.44 | 6.56% | $3.8B | $3.9B |
| Q3 2025 | Oct 28, 2025 | $9.65 | $11.83 | 22.53% | $3.6B | $3.8B |
| Q2 2025 | Aug 1, 2025 | $8.43 | $12.89 | 52.89% | $3.3B | $3.7B |
| Q1 2025 | Apr 29, 2025 | $8.62 | $8.22 | -4.66% | $3.2B | $3.0B |
| Q4 2024 | Feb 4, 2025 | $11.28 | $12.07 | 6.98% | $3.7B | $3.8B |
| Q3 2024 | Oct 31, 2024 | $11.70 | $12.46 | 6.54% | $3.7B | $3.7B |
| Q2 2024 | Aug 1, 2024 | $10.62 | $11.56 | 8.87% | $3.4B | $3.5B |
| Q1 2024 | May 2, 2024 | $10.17 | $9.55 | -6.11% | $3.2B | $3.1B |
| Q4 2023 | Feb 2, 2024 | $10.73 | $11.86 | 10.52% | $3.3B | $3.4B |
| Q3 2023 | Nov 2, 2023 | $10.68 | $11.59 | 8.50% | $3.2B | $3.4B |
| Q2 2023 | Aug 3, 2023 | $9.85 | $10.24 | 3.99% | $3.0B | $3.2B |
| Q1 2023 | May 4, 2023 | $9.52 | $10.09 | 5.99% | $3.0B | $3.2B |
| Q4 2022 | Feb 3, 2023 | $10.25 | $12.56 | 22.57% | $3.1B | $3.4B |
| Q3 2022 | Nov 3, 2022 | $9.76 | $11.14 | 14.17% | $2.9B | $2.9B |
| Q2 2022 | Aug 3, 2022 | $8.62 | $9.77 | 13.36% | $2.8B | $2.9B |
| Q1 2022 | May 4, 2022 | $9.72 | $11.49 | 18.15% | $2.7B | $3.0B |
| Q4 2021 | Feb 4, 2022 | $20.40 | $23.72 | 16.26% | $4.6B | $5.0B |
| Q3 2021 | Nov 4, 2021 | $10.35 | $15.37 | 48.57% | $2.7B | $3.5B |

## Frequently Asked Questions

### When did Regeneron (REGN) last report earnings?

Regeneron last reported on Jul 30, 2026, covering fiscal Q2 2026.

### Did REGN beat earnings estimates?

Yes. Regeneron reported EPS of $14.29 for Q2 2026 against a $10.16 estimate — a 40.69% beat.

### How much revenue did REGN report last quarter?

Regeneron reported $4.3B in revenue for Q2 2026, against a consensus estimate of $3.8B.

## Similar Stocks

- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [NTLA](https://www.lighthorse.io/tickers/ntla) — Intellia Therapeutics, Inc. - Common Stock
- [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [VIR](https://www.lighthorse.io/tickers/vir) — Vir Biotechnology, Inc. - Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).